Recon: US cuts $700M in funding for Moderna bird flu vaccine; FDA approves Alcon’s dry eye drug

• As the FDA and NIH eschew animal testing, startup raises $40 million for lab-grown organs (STAT)
• Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements (STAT)
• Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss (Endpoints)
• Large pharma companies spell out reasons why tariffs will harm US investments (Endpoints)
• US cancels more than $700 million funding for Moderna bird flu vaccine (Reuters)
• US FDA approves Alcon's new dry-eye drug (Reuters)
• RFK Jr. Slams Medical Journals, Floats In-House Publishing Plan (Bloomberg)
• RFK Jr’s ‘Maha’ report found to contain citations to nonexistent studies (The Guardian)

• Sanofi’s vaccine tech transfer in Vietnam; Almac’s £1B+ revenue milestone (Endpoints)
• Brazil declared free of foot-and-mouth disease without vaccination (Reuters)
• China investigating former head of food and drug watchdog (Reuters)
• FDA finds Chinese lab copied or falsified data, endangering patients (MedTech Dive)
• UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth (MedTech Insight)

• PillPack founders’ new health care marketplace has deep roots with Amazon (STAT)
• CHAI’s ‘assurance lab’ effort is dead. Long live the assurance lab. (STAT)
• DNA giant Illumina spawned an ecosystem of competitors and customers (Endpoints)
• FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval (Endpoints)
• Taysha’s pivotal trial plans; Keros to stop work on PAH drug, lay off 45% of staff (Endpoints)
• Oric locks down cash for Phase 3 prostate cancer trial with early data in hand (Endpoints)
• PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy (Endpoints)
• Intellia reports case of liver toxicity in ATTR gene editing study (Endpoints)
• Omada Health targets valuation of over $1 billion in US IPO (Reuters)
• Cancer Drugs Cost More Than Ever. They Often Don't Extend Lives (Bloomberg)

• AI-based mammography is here, and it has a trust problem (STAT)
• The medtech IPO window is finally open. Or is it? (MedTech Dive)
• US court blocks Trump’s sweeping tariffs (MedTech Dive)
• Abbott wins FDA approval for mitral valve replacement device, teeing up Edwards competition (MedTech Dive)

• General Mills to cut jobs as part of multi-year restructuring plan (Food Dive)
•  Töst aims to reach moderate drinkers with sophisticated mocktails (Food Dive)
• FSAI Seeks Public Input on Food Hygiene Rating Scheme (Food Safety)
• USDA Secretary Rollins Increases Funding to Reimburse States for Food Safety Inspections (Food Safety)

• Amid measles outbreak, Texas is poised to make vaccine exemptions for kids easier (STAT)
• How we beat anti-vaccination bills in North Dakota (STAT)
• With aura readings and a Lauryn Hill concert, Philip Morris rolls out a new tobacco product in the U.S. (STAT)
• With Covid vaccine decisions, RFK Jr. unleashes an unfettered assault on public health (STAT)
• Another Lever That Can Be Used to Slow Inflation: Healthcare (Bloomberg)